Product Reports Resources Pricing Login Book a demo

AbSci

Biotech & Life Sciences · Vancouver, United States · Founded 2011 · IPO 2021

The global leader in cutting-edge protein production technologies committed to reducing costs in the biopharmaceutical industry MoreLess

AbSci is a pioneering company in the biotech industry, focused on revolutionizing protein expression and biomanufacturing. The company operates in the biopharmaceutical market, serving clients that include pharmaceutical companies, biotech firms, and research institutions. AbSci's core innovation lies in its advanced protein expression platform, which features a semi-oxidizing cytoplasm and a dual inducible promoter system. These technologies allow for precise control over protein production rates, leading to higher quality and efficiency in drug manufacturing.

One of AbSci's standout offerings is SoluPure, a chromatography-free purification method that simplifies the downstream processing of proteins. This method removes bottlenecks typically associated with traditional purification techniques, making the production process faster and more cost-effective. AbSci's high-throughput workflow can generate cell lines that produce folded, active protein products in as little as three months, significantly reducing the time and resources needed for drug development.

AbSci's business model is built around providing cutting-edge biomanufacturing solutions that introduce efficiencies and cost savings to the biotech industry. The company makes money by partnering with pharmaceutical and biotech companies, offering them proprietary technologies and services that enhance their drug discovery and manufacturing processes. By doing so, AbSci aims to replace traditional mammalian expression platforms, such as CHO cells, with its more efficient and scalable solutions.

The company is supported by a group of experienced investors and is driven by a team of passionate, imaginative, and accomplished scientists. These professionals are dedicated to challenging established industry practices and creating extraordinary tools for drug discovery and manufacturing.

In summary, AbSci is a disruptive force in the biotech industry, offering innovative solutions that streamline protein production and purification, ultimately transforming how life-changing biologics are made.

Keywords: Biotech, Protein Expression, Biomanufacturing, Drug Discovery, SoluPure, Purification, High-Throughput, Cytoplasm, Promoter System, Biopharmaceutical.

Valuation $1.20B
Revenue $5.7M
Total funding $100–500M

Talent graph

AbSci's talent

Book a demo to see the people
Employees mapped 180 incl. 18 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 22 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

23 investors on AbSci's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Phoenix Venture Partners
Series B+ 22 investors entered at this stage
AGC
Greenbridge Partners
Oregon Entrepreneurs Network
KBI Biopharma
Jsr
JSR Life Sciences
Columbia Ventures Corporation
WRF Capital
Casdin Capital
Redmile Group
ArrowMark Partners
Merck Global Health Innovation Fund
D1 Capital Partners
Fidelity Investments
Perceptive Advisors
Irving Investors
AMD
Adage Capital
Invus
Eli Lilly
BVF Partners
Columbia Threadneedle Investments

Global footprint

Where AbSci has talent and traffic

Workforce by country
10 countries with
team presence
🇺🇸 United States86%
🇷🇸 Serbia5.2%
🇨🇭 Switzerland2.9%
🇬🇧 United Kingdom1.5%
🇳🇱 Netherlands0.7%
Top 5 of 10 shown
Web traffic by country
31K monthly visits
across markets
🇺🇸 United States31.6%
🇬🇧 United Kingdom14.2%
🏳️ Korea12.6%
🏳️ Republic of12.6%
🇨🇦 Canada10.3%
Top 5 markets shown

Patent intelligence

$7M patent portfolio · 25 active families

Estimated portfolio value
$7M
0.56% of market cap · 72.1× smaller than top peer Genmab ($488M)
25 active patent families
Where AbSci innovates Antiendomysial antibodiesBioinformaticsBiological organismCellCell biology

Where AbSci concentrates vs peers

Each axis is a top-10 topic across AbSci and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about AbSci

An AI-synthesized read of the highest-engagement posts about AbSci on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See AbSci on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.